0000899243-21-002762.txt : 20210121
0000899243-21-002762.hdr.sgml : 20210121
20210121192623
ACCESSION NUMBER: 0000899243-21-002762
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210119
FILED AS OF DATE: 20210121
DATE AS OF CHANGE: 20210121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Leen Ann M.
CENTRAL INDEX KEY: 0001763026
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39409
FILM NUMBER: 21543318
MAIL ADDRESS:
STREET 1: 5 WEST FORSYTH STREET
STREET 2: SUITE 200
CITY: JACKSONVILLE
STATE: FL
ZIP: 32202
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allovir, Inc.
CENTRAL INDEX KEY: 0001754068
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 831971007
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 139 MAIN STREET, SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 433-2605
MAIL ADDRESS:
STREET 1: 139 MAIN STREET, SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: ViraCyte, Inc.
DATE OF NAME CHANGE: 20180924
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-19
0
0001754068
Allovir, Inc.
ALVR
0001763026
Leen Ann M.
C/O ALLOVIR, INC.
139 MAIN STREET, SUITE 500
CAMBRIDGE
MA
02142
0
1
0
0
Chief Scientific Officer
Common Stock
2020-11-30
5
G
0
E
60394
0.00
D
0
D
Common Stock
2020-11-30
5
G
0
E
60394
0.00
A
60394
I
See Footnote
Common Stock
2021-01-19
4
A
0
28000
0.00
A
28000
D
Common Stock
2436773
I
See Footnote
Stock Option (Right to Buy)
42.15
2021-01-19
4
A
0
52000
0.00
A
2031-01-19
Common Stock
52000
52000
D
On November 30, 2020, the Reporting Person transferred 60,394 shares to the Ann M. Leen Management Trust dated 7/3/2019, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.
Shares held by the Ann M. Leen Management Trust dated 10/31/2019, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.
/s/ Brett Hagen, as Attorney-in-Fact
2021-01-21